Key result
NOACs emerge as an oral treatment option for cancer-associated VTE.
Why the study?
With NOACs emerging as a new option alongside standard LMWH for cancer-associated thrombosis, an in-depth understanding of drug properties, efficacy, safety, and economic costs is needed to select appropriate treatment for individual cancer patients.
Do new oral anticoagulants (NOACs) provide an effective, safe, and cost-effective alternative to low molecular weight heparin for the treatment of cancer-associated venous thromboembolism?
Do new oral anticoagulants (NOACs) provide an effective, safe, and cost-effective alternative to low molecular weight heparin for the treatment of cancer-associated venous thromboembolism?
This review provides an overview of the emerging role of NOACs as an alternative to LMWH for managing cancer-associated venous thromboembolism, considering efficacy, safety, and economic costs.
Answers are grounded in this paper and cite their sources.
NOACs may offer an alternative to LMWH for cancer-associated VTE; leaves open definitive efficacy, safety, and cost comparisons pending prospective trials.
Venous thromboembolism (VTE) is associated with increased morbidity and mortality, decreased quality of life, and higher economic burden in patients with cancer. Currently, the treatment of VTE in patients with cancer is particularly challenging. For many years, low molecular weight heparin (LMWHs) has been the standard for the treatment of cancer-associated VTE. Recently, the introduction of new oral anticoagulants (NOACs) may offer an oral anticoagulant option for some patients with cancer-associated thrombosis (CAT) as a growing body of literature supports the use of NOACs in the setting of CAT. With the use of NOAC as a new option in the management of CAT, clinicians now face several choices for the individual cancer patient with VTE. We need a more in-depth understanding of the drug properties, efficacy and safety, economic analysis that allows us to choose the most appropriate treatment for each patient. In the review, we will present an overview of CAT management, discuss the available evidence, economic costs for NOACs in the treatment of CAT, and seek to provide the best range of treatments for cancer patients.
No takes yet. Share an insight, caveat, or question.
Wumaier et al. (2022) conducted a review in Cancer-associated venous thromboembolism. New oral anticoagulants (NOACs) vs. Low molecular weight heparin (LMWHs) was evaluated. New oral anticoagulants (NOACs) offer an emerging oral treatment option for cancer-associated venous thromboembolism, prompting a review of their efficacy, safety, and economic costs.
Synapse has enriched 10 related papers. Consider them for comparative context: